Lieke Maas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lieke Maas has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Mickaël Hiligsmann
Maastricht University
13 shared publications - Annelies Boonen
Care and Public Health Research Institute (CAPHRI), Maastricht University , Maastricht
4 shared publications - Caroline E. Wyers
Department of Internal Medicine, VieCuri Medical Center , 5912 BL Venlo
4 shared publications - Joop Pw van Den Bergh
Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands
4 shared publications - C. Contreras-Meca
Radiomics.bio
3 shared publications - Sander Martijn Job van Kuijk
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands
3 shared publications
Latest Publications
- Open Access
A multicountry trial-based and model-based economic evaluation of youth mental health interventions: a protocol for assessing the short- and long-term societal impacts of YOUTHreach interventions
Background: Mental health problems among young people impose a burden extending beyond healthcare, including impaired health-related quality of life and high societal costs from disrupted education, lost productivity, and informal care. Youth-friendly interventions may reduce this burden by providing early support and preventing escalation. However, their broader societal economic impact remains insufficiently explored. Evaluations incorporating consequences beyond healthcare and longer time horizons can better capture their societal value. Methods: This protocol outlines harmonised trial-based and model-based economic evaluations of YEAH, SELFIE, and MOST, three mental health interventions for young people aged 12–25. Each intervention will be compared separately against care as usual over 12 months, with longer-term costs and outcomes projected at 2, 3, 5, and 10 years. Multicountry participant data will be pooled, using a prespecified reference country for base-case costing and methodological guidance. A harmonised, context-specific Resource Use Measurement instrument was developed to capture healthcare and broader societal resource use consistently across participating countries and to support evaluation of the economic impact of youth mental health interventions from a multicountry perspective. Uncertainty will be assessed through sensitivity and scenario analyses. Discussion: The proposed harmonised methodological framework will support consistent estimation of the short- and long-term cost-effectiveness of three youth-friendly mental health interventions. It will enable comparison of intervention-specific results generated using different trial designs and support consistent estimation of costs and outcomes across the three interventions. The context-specific Resource Use Measurement instrument will further support consistent measurement of healthcare utilisation, productivity losses, and informal care across the economic evaluations. Conclusion: By integrating trial-based evidence with long-term modelling and standardised measurement of resource use, this study aims to generate robust, policy-relevant evidence to inform health technology assessment and decision-making for youth mental health interventions. The context-specific Resource Use Measurement instrument is also intended to support future economic evaluations of mental health interventions conducted across multiple countries.
Open AccessA multicountry trial-based and model-based economic evaluation of youth mental health interventions: a protocol for assessing the short- and long-term societal impacts of YOUTHreach interventions
Background: Mental health problems among young people impose a burden extending beyond healthcare, including impaired health-related quality of life and high societal costs from disrupted education, lost productivity, and informal care. Youth-friendly interventions may reduce this burden by providing early support and preventing escalation. However, their broader societal economic impact remains insufficiently explored. Evaluations incorporating consequences beyond healthcare and longer time horizons can better capture their societal value. Methods: This protocol outlines harmonised trial-based and model-based economic evaluations of YEAH, SELFIE, and MOST, three mental health interventions for young people aged 12–25. Each intervention will be compared separately against care as usual over 12 months, with longer-term costs and outcomes projected at 2, 3, 5, and 10 years. Multicountry participant data will be pooled, using a prespecified reference country for base-case costing and methodological guidance. A harmonised, context-specific Resource Use Measurement instrument was developed to capture healthcare and broader societal resource use consistently across participating countries and to support evaluation of the economic impact of youth mental health interventions from a multicountry perspective. Uncertainty will be assessed through sensitivity and scenario analyses. Discussion: The proposed harmonised methodological framework will support consistent estimation of the short- and long-term cost-effectiveness of three youth-friendly mental health interventions. It will enable comparison of intervention-specific results generated using different trial designs and support consistent estimation of costs and outcomes across the three interventions. The context-specific Resource Use Measurement instrument will further support consistent measurement of healthcare utilisation, productivity losses, and informal care across the economic evaluations. Conclusion: By integrating trial-based evidence with long-term modelling and standardised measurement of resource use, this study aims to generate robust, policy-relevant evidence to inform health technology assessment and decision-making for youth mental health interventions. The context-specific Resource Use Measurement instrument is also intended to support future economic evaluations of mental health interventions conducted across multiple countries.
- Open Access
- 9 August 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (7) , 873-877
The economic and societal burden associated with Post-COVID in the Netherlands: a cost-of-illness and quality of life study protocol
1. Post-COVID (also called Long-COVID) is an infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitt...
- 9 August 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (7) , 873-877
Open AccessThe economic and societal burden associated with Post-COVID in the Netherlands: a cost-of-illness and quality of life study protocol
1. Post-COVID (also called Long-COVID) is an infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitt...
- Open Access
- 26 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Protocol for the Efficacy, Process, and Economic Evaluation of the CARE-FIT eHealth Intervention Targeting Physical Activity, Sleep, and Stress in Cancer Patients: A Randomised Controlled Trial (Preprint)
BACKGROUND Cancer incidence is steadily increasing worldwide. Reduced physical activity (PA), sleep disturbances, and high levels of psychological stress are prevalent within cancer patients. These impairments reduce quality of life and functional recovery and are linked to increased societal costs. Despite this, support to improve PA and sleep quality and reduce psychological stress remains insufficiently integrated into routine oncological care. Healthcare professionals face structural and organisational barriers to providing lifestyle guidance, while patients report unmet supportive care needs. eHealth interventions offer opportunities to deliver tailored lifestyle support. However, evidence on the efficacy, economic outcomes, and implementation of eHealth interventions embedded within routine oncological care remains limited. OBJECTIVE This study protocol describes the design of a randomised controlled trial that assesses the efficacy of CARE-FIT, a blended eHealth intervention integrated into routine oncological care, targeting PA, sleep quality, and psychological stress. The study consists of an efficacy evaluation, a process evaluation, and both trial- and model-based economic evaluations. METHODS A non-blinded, parallel-group, randomised controlled trial was conducted across hospitals, rehabilitation centres, and physiotherapy practices in the Netherlands. Healthcare organisations were stratified and randomised to either the CARE-FIT intervention plus usual care or usual care alone. Adult patients diagnosed with cancer from the time of diagnosis up to 1 year after completion of curative treatment were eligible. Participants receiving CARE-FIT were provided with theory-informed, tailored online advisory sessions and modules and an activity tracker throughout the 12-week intervention period. Healthcare professionals referred patients to the intervention during routine consultations. Outcomes were assessed at baseline, 12 weeks, and 24 weeks. For the efficacy evaluation, primary outcomes included objectively measured PA and self-reported PA, sleep quality, and psychological stress. Secondary outcomes included fatigue and health-related quality of life. Multilevel linear mixed-effects models were used in accordance with the intention-to-treat principle. For the process evaluation, intervention use, appreciation, and implementation experiences among patients and healthcare professionals were assessed. The economic evaluation comprised cost-effectiveness and cost-utility analyses conducted from a societal perspective using both trial-based and model-based approaches, alongside a budget impact analysis. RESULTS Participants were recruited from September 2025 to April 2026 through 41 participating healthcare organisations, including 15 hospital departments, 4 rehabilitation centres, and 22 physiotherapy practices. The study aimed to include 356 participants, with 178 participants in each condition. CONCLUSIONS The described trial will provide comprehensive evidence regarding the clinical efficacy, economic outcomes, and implementation of a blended eHealth lifestyle intervention embedded in routine oncological care. By integrating these components within a multicentre design, the study will provide insights into the feasibility and sustainable implementation of lifestyle support for individuals living with and beyond cancer. CLINICALTRIAL ISRCTN Registry ISRCTN61846887; https://www.isrctn.com/ISRCTN61846887
- 26 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessProtocol for the Efficacy, Process, and Economic Evaluation of the CARE-FIT eHealth Intervention Targeting Physical Activity, Sleep, and Stress in Cancer Patients: A Randomised Controlled Trial (Preprint)
BACKGROUND Cancer incidence is steadily increasing worldwide. Reduced physical activity (PA), sleep disturbances, and high levels of psychological stress are prevalent within cancer patients. These impairments reduce quality of life and functional recovery and are linked to increased societal costs. Despite this, support to improve PA and sleep quality and reduce psychological stress remains insufficiently integrated into routine oncological care. Healthcare professionals face structural and organisational barriers to providing lifestyle guidance, while patients report unmet supportive care needs. eHealth interventions offer opportunities to deliver tailored lifestyle support. However, evidence on the efficacy, economic outcomes, and implementation of eHealth interventions embedded within routine oncological care remains limited. OBJECTIVE This study protocol describes the design of a randomised controlled trial that assesses the efficacy of CARE-FIT, a blended eHealth intervention integrated into routine oncological care, targeting PA, sleep quality, and psychological stress. The study consists of an efficacy evaluation, a process evaluation, and both trial- and model-based economic evaluations. METHODS A non-blinded, parallel-group, randomised controlled trial was conducted across hospitals, rehabilitation centres, and physiotherapy practices in the Netherlands. Healthcare organisations were stratified and randomised to either the CARE-FIT intervention plus usual care or usual care alone. Adult patients diagnosed with cancer from the time of diagnosis up to 1 year after completion of curative treatment were eligible. Participants receiving CARE-FIT were provided with theory-informed, tailored online advisory sessions and modules and an activity tracker throughout the 12-week intervention period. Healthcare professionals referred patients to the intervention during routine consultations. Outcomes were assessed at baseline, 12 weeks, and 24 weeks. For the efficacy evaluation, primary outcomes included objectively measured PA and self-reported PA, sleep quality, and psychological stress. Secondary outcomes included fatigue and health-related quality of life. Multilevel linear mixed-effects models were used in accordance with the intention-to-treat principle. For the process evaluation, intervention use, appreciation, and implementation experiences among patients and healthcare professionals were assessed. The economic evaluation comprised cost-effectiveness and cost-utility analyses conducted from a societal perspective using both trial-based and model-based approaches, alongside a budget impact analysis. RESULTS Participants were recruited from September 2025 to April 2026 through 41 participating healthcare organisations, including 15 hospital departments, 4 rehabilitation centres, and 22 physiotherapy practices. The study aimed to include 356 participants, with 178 participants in each condition. CONCLUSIONS The described trial will provide comprehensive evidence regarding the clinical efficacy, economic outcomes, and implementation of a blended eHealth lifestyle intervention embedded in routine oncological care. By integrating these components within a multicentre design, the study will provide insights into the feasibility and sustainable implementation of lifestyle support for individuals living with and beyond cancer. CLINICALTRIAL ISRCTN Registry ISRCTN61846887; https://www.isrctn.com/ISRCTN61846887
- 15 June 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (6) , 1-3
From Model validation to policy resilience: stress testing healthcare Systems with AI and cross-sectorial methodology
- 15 June 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (6) , 1-3
From Model validation to policy resilience: stress testing healthcare Systems with AI and cross-sectorial methodology
- Open Access
- 13 January 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (2) , 303-312
Cost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands
Given the potential of artificial intelligence (AI) and the increasing importance of understanding AI's economic impact, this study aims to provide insights into the potential cost-effectiveness of an AI tool in the response prediction to neoadjuvant chemoradiotherapy (nCRT) of Stage II-III LARC patients in comparison to usual care (UC). This study included a state-transition Markov model from a Dutch societal perspective. Quality-adjusted life years (QALY) and costs were simulated over a 10-year horizon. Sensitivity analyses and a threshold analysis were performed. Results were presented as incremental cost-effectiveness ratios. With incremental cost savings of -€2,530,000 per QALY gained per 1000 patients, the AI is dominant in the base-case. Main drivers of cost-effectiveness were the clinical complete response incidence and specificity of the tool. Cost-effectiveness was maintained at a cost of €1,100 and €2,100 for an AI performance of 0.85 and 0.90. Findings of this study present the economic impact of a hypothetical AI-based approach to treatment response prediction in Stage II-III LARC patients who receive nCRT and are eligible for consecutive surgery. The results of this study highlight the complexity of healthcare decision-making in tools that could be cost-saving yet yield lower effectiveness when parameters are uncertain.
- 13 January 2026
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (2) , 303-312
Open AccessCost-effectiveness analysis of artificial intelligence (AI) for response prediction of neoadjuvant radio(chemo)therapy in locally advanced rectal cancer (LARC) in the Netherlands
Given the potential of artificial intelligence (AI) and the increasing importance of understanding AI's economic impact, this study aims to provide insights into the potential cost-effectiveness of an AI tool in the response prediction to neoadjuvant chemoradiotherapy (nCRT) of Stage II-III LARC patients in comparison to usual care (UC). This study included a state-transition Markov model from a Dutch societal perspective. Quality-adjusted life years (QALY) and costs were simulated over a 10-year horizon. Sensitivity analyses and a threshold analysis were performed. Results were presented as incremental cost-effectiveness ratios. With incremental cost savings of -€2,530,000 per QALY gained per 1000 patients, the AI is dominant in the base-case. Main drivers of cost-effectiveness were the clinical complete response incidence and specificity of the tool. Cost-effectiveness was maintained at a cost of €1,100 and €2,100 for an AI performance of 0.85 and 0.90. Findings of this study present the economic impact of a hypothetical AI-based approach to treatment response prediction in Stage II-III LARC patients who receive nCRT and are eligible for consecutive surgery. The results of this study highlight the complexity of healthcare decision-making in tools that could be cost-saving yet yield lower effectiveness when parameters are uncertain.
- Open Access
- 11 July 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1023-1036
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related death. Cirrhosis is a major contributing factor, accounting for over 90% of HCC cases. With the high mortality rate of HCC, earlier detection of HCC is critical. When added to magnetic resonance imaging (MRI), artificial intelligence (AI) has been shown to improve HCC detection. Nonetheless, to date no cost-effectiveness analyses have been conducted on an AI tool to enhance earlier HCC detection. This study reports on the cost-effectiveness of detection of liver lesions with AI improved MRI in the surveillance for HCC in patients with a cirrhotic liver compared to usual care (UC). The model structure included a decision tree followed by a state-transition Markov model from an Italian healthcare perspective. Lifetime costs and quality-adjusted life years (QALY) were simulated in cirrhotic patients at risk of HCC. One-way sensitivity analyses and two-way sensitivity analyses were performed. Results were presented as incremental cost-effectiveness ratios (ICER). For patients receiving UC, the average lifetime costs per 1,000 patients were €16,604,800 compared to €16,610,250 for patients receiving the AI approach. With a QALY gained of 0.55 and incremental costs of €5,000 for every 1,000 patients, the ICER was €9,888 per QALY gained, indicating cost-effectiveness with the willingness-to-pay threshold of €33,000/QALY gained. Main drivers of cost-effectiveness included the cost and performance (sensitivity and specificity) of the AI tool. This study suggests that an AI-based approach to earlier detect HCC in cirrhotic patients can be cost-effective. By incorporating cost-effective AI-based approaches in clinical practice, patient outcomes and healthcare efficiency are improved.
- 11 July 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1023-1036
Open AccessCost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related death. Cirrhosis is a major contributing factor, accounting for over 90% of HCC cases. With the high mortality rate of HCC, earlier detection of HCC is critical. When added to magnetic resonance imaging (MRI), artificial intelligence (AI) has been shown to improve HCC detection. Nonetheless, to date no cost-effectiveness analyses have been conducted on an AI tool to enhance earlier HCC detection. This study reports on the cost-effectiveness of detection of liver lesions with AI improved MRI in the surveillance for HCC in patients with a cirrhotic liver compared to usual care (UC). The model structure included a decision tree followed by a state-transition Markov model from an Italian healthcare perspective. Lifetime costs and quality-adjusted life years (QALY) were simulated in cirrhotic patients at risk of HCC. One-way sensitivity analyses and two-way sensitivity analyses were performed. Results were presented as incremental cost-effectiveness ratios (ICER). For patients receiving UC, the average lifetime costs per 1,000 patients were €16,604,800 compared to €16,610,250 for patients receiving the AI approach. With a QALY gained of 0.55 and incremental costs of €5,000 for every 1,000 patients, the ICER was €9,888 per QALY gained, indicating cost-effectiveness with the willingness-to-pay threshold of €33,000/QALY gained. Main drivers of cost-effectiveness included the cost and performance (sensitivity and specificity) of the AI tool. This study suggests that an AI-based approach to earlier detect HCC in cirrhotic patients can be cost-effective. By incorporating cost-effective AI-based approaches in clinical practice, patient outcomes and healthcare efficiency are improved.
- Open Access
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (8) , 1211-1218
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries
With increasing efforts of streamlining market access of innovative drugs, current acceptance of health technology assessment (HTA) bodies on non-traditional trial designs is still unclear. The aim of this study was to assess the perspective of drug developers on the acceptance of non-traditional trial designs by HTA bodies in Europe. Eleven semi-structured interviews were conducted with experts to gain insights on their perception of non-traditional trial design acceptance by HTA bodies from the Netherlands, Germany, United Kingdom, Sweden, and France. Future perspectives on and recommendations for facilitating the acceptance of non-traditional trials were provided. All experts highlighted the HTA bodies' preference for randomized controlled trials over non-traditional trial designs. The degree of acceptance varied between countries. Experts recommended multistakeholder discussions between drug developers and HTA bodies for early scientific advice and re-evaluation of evidence requirements. The EU-HTA regulation was viewed as both a potential opportunity for harmonization and limiting innovative approach. The results of this study highlighted significant variations in the acceptance of non-traditional trial designs by HTA bodies across Europe. Actions are needed to facilitate a more progressive view on non-traditional clinical trial designs to ensure fast patient access to highly innovative treatments.
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (8) , 1211-1218
Open AccessQualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries
With increasing efforts of streamlining market access of innovative drugs, current acceptance of health technology assessment (HTA) bodies on non-traditional trial designs is still unclear. The aim of this study was to assess the perspective of drug developers on the acceptance of non-traditional trial designs by HTA bodies in Europe. Eleven semi-structured interviews were conducted with experts to gain insights on their perception of non-traditional trial design acceptance by HTA bodies from the Netherlands, Germany, United Kingdom, Sweden, and France. Future perspectives on and recommendations for facilitating the acceptance of non-traditional trials were provided. All experts highlighted the HTA bodies' preference for randomized controlled trials over non-traditional trial designs. The degree of acceptance varied between countries. Experts recommended multistakeholder discussions between drug developers and HTA bodies for early scientific advice and re-evaluation of evidence requirements. The EU-HTA regulation was viewed as both a potential opportunity for harmonization and limiting innovative approach. The results of this study highlighted significant variations in the acceptance of non-traditional trial designs by HTA bodies across Europe. Actions are needed to facilitate a more progressive view on non-traditional clinical trial designs to ensure fast patient access to highly innovative treatments.
- 4 May 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (6) , 837-839
Unleashing economic potential of AI-driven technology to prevent adverse events and sub-optimal treatment
- 4 May 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (6) , 837-839
Unleashing economic potential of AI-driven technology to prevent adverse events and sub-optimal treatment